Sleep Apnea Syndrome (SAS) Clinical Practice Guidelines 2020
Sleep Apnea Syndrome (SAS) Clinical Practice Guidelines 2020
复制标题
DOI：
10.1016/j.resinv.2021.08.010
复制
发表时间：
2022-01-02
影响因子：
3.1
通讯作者：
Momomura, Shin-Ichi
中科院分区：
文献类型：
--
作者：
Akashiba, Tsuneto;Inoue, Yuichi;Momomura, Shin-Ichi
据报道，睡眠呼吸障碍（SDB）的患病率非常高。在SDB中，阻塞性睡眠呼吸暂停（OSA）的发病率高于以前认为的，不仅在西方国家，而且在包括日本在内的东方国家，患有中度至重度OSA的患者约占成年男性的20%和绝经后女性的10%。自1998年健康保险覆盖以来，使用持续气道正压通气（CPAP）治疗睡眠呼吸暂停的患者数量急剧增加，日本的患者数量即将超过50万人。虽然《成人睡眠呼吸暂停综合征（SAS）诊断和治疗指南》于2005年出版，但在日本呼吸学会和卫生部“难治性呼吸疾病和肺动脉高压调查研究”小组的监督和合作下，根据最新趋势制定了一项新指南，以说明标准医疗护理，劳动和福利等相关学术团体，包括日本睡眠研究学会，除了参考以前的指南。由于睡眠呼吸暂停是一个跨学科的领域，涵盖了许多领域，本指南包括36个临床问题（CQ）。在英文版中，显示了从CQ16到36的SAS治疗和管理。日文版于二零二零年七月出版，并于二零二一年七月获准在日本作为医学信息网络分发服务（Minds）临床实践指南之一出版。(C)2021作者由Elsevier B.V.代表日本呼吸学会出版。
The prevalence of sleep disordered breathing (SDB) is reportedly very high. Among SDBs, the incidence of obstructive sleep apnea (OSA) is higher than previously believed, with patients having moderate-to-severe OSA accounting for approximately 20% of adult males and 10% of postmenopausal women not only in Western countries but also in Eastern countries, including Japan. Since 1998, when health insurance coverage became available, the number of patients using continuous positive airway pressure (CPAP) therapy for sleep apnea has increased sharply, with the number of patients about to exceed 500,000 in Japan. Although the "Guidelines for Diagnosis and Treatment of Sleep Apnea Syndrome (SAS) in Adults" was published in 2005, a new guideline was prepared in order to indicate the standard medical care based on the latest trends, as supervised by and in cooperation with the Japanese Respiratory Society and the "Survey and Research on Refractory Respiratory Diseases and Pulmonary Hypertension" Group, of Ministry of Health, Labor and Welfare and other related academic societies, including the Japanese Society of Sleep Research, in addition to referring to the previous guidelines. Because sleep apnea is an interdisciplinary field covering many areas, this guideline was prepared including 36 clinical questions (CQs). In the English version, therapies and managements for SAS, which were written from CQ16 to 36, were shown. The Japanese version was published in July 2020 and permitted as well as published as one of the Medical Information Network Distribution Service (Minds) clinical practice guidelines in Japan in July 2021. (C) 2021 The Authors Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.